Controversies in the management of premenopausal women: Role of OS/OA and fertility

E-session 357 Add to My Agenda

Expert:

Olivia Pagani, expert of session 'Controversies in the management of premenopausal women: Role of OS/OA and fertility'

Olivia Pagani
Oncology Institute of Southern Switzerland
Lugano, Switzerland

Discussant: Shani Paluch-Shimon
Sheba Medical Center, Breast Cancer Service for Young Women, Tel Hashomer, Israel

View slides

Enter the recorded session

Share on:

Question: Dear Dr. Pagani, Thanks for your very clear presentation. Can I please ask which patients are you selecting nowadays for exemestane plus aLHRH and for tamoxifen plus aLHRH? Thanks

Answer: Dear colleague if a patient is at sufficient risk to deserve LHRH (e.g. N+, large tumor, high proliferation rate) i prescribe Exemestane (TEXT results). If then she does not tolerate it I switch to Tamoxifen while maintaining the LHRH Best regards, Olivia Pagani


23
Jun 2016
18:15-19:00 CET

Top